Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding proposal offer from biotech giant Biogen to acquire the remaining shares of ...

SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.

Sage Therapeutics rejected a takeover offer from Biogen (BIIB) and said it started a process to review its strategic alternatives. Sage rose 5.6%. Sage's board will look at a range of ...

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics was in focus after it rejected Biogen's acquisition proposal. Sage Therapeutics stock gained after it ...

The reimbursement from Biogen to Sage for R&D expenses pursuant to the Sage/Biogen Collaboration and License Agreement was $1.3 million in the fourth quarter of 2024 compared to $8.3 million in ...

Read Sage Therapeutics Initiates Strategic Review Process and Rejects Proposal from Biogen at ETF Daily News On January 27, 2025, Sage Therapeutics, Inc. filed an 8-K report with the Securities ...